Clinical Trial Update: Dolutegravir + Rilpivirine Switch Study (DORISS) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating switching to a dolutegravir + rilpivirine regimen in virologically controlled HIV infection has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dolutegravir (dolutegravir)
• rilpivirine (rilpivirine)

Snippet

Sponsor: Nantes University Hospital | Conditions: HIV Infection, HAART-treated | Phase 2, Phase 3 | Status: WITHDRAWN